These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 17418409)

  • 1. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
    Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
    Hendrix ND; Wu R; Kuick R; Schwartz DR; Fearon ER; Cho KR
    Cancer Res; 2006 Feb; 66(3):1354-62. PubMed ID: 16452189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
    Wu R; Zhai Y; Fearon ER; Cho KR
    Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
    Sarrió D; Moreno-Bueno G; Sánchez-Estévez C; Bañón-Rodríguez I; Hernández-Cortés G; Hardisson D; Palacios J
    Hum Pathol; 2006 Aug; 37(8):1042-9. PubMed ID: 16867867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
    Schwartz DR; Wu R; Kardia SL; Levin AM; Huang CC; Shedden KA; Kuick R; Misek DE; Hanash SM; Taylor JM; Reed H; Hendrix N; Zhai Y; Fearon ER; Cho KR
    Cancer Res; 2003 Jun; 63(11):2913-22. PubMed ID: 12782598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
    Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.
    Tanwar PS; Kaneko-Tarui T; Lee HJ; Zhang L; Teixeira JM
    Carcinogenesis; 2013 Apr; 34(4):893-901. PubMed ID: 23276799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.
    Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM
    PLoS One; 2011; 6(6):e20715. PubMed ID: 21695255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
    Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.